10 research outputs found
Recommended from our members
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy
W1021 Chronic Hepatitis C Virus (HCV) Infection in a Cohort of Postmenopausal Irish Women Contributes to the Development of Bone Fractures
Sa1909 Accelerated Induction Therapy With Infliximab as a Rescue Treatment in Acute Severe Steroid Refractory Colitis
Sa1105 Short Interval From Diagnosis to Rescue Infliximab is Associated With Increased Cumulative Risk of Colectomy in Acute Severe Ulcerative Colitis
Sa1908 Avoidance of Repeat Surgery With Endoscopic Balloon Dilatation of Anastomotic Strictures in Crohn's Disease
Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer
Background. Percutaneous endoscopic gastrostomy (PEG) placement using the “pull” technique is commonly utilized for providing nutritional support in head and neck cancer (HNC) patients, but it may be complicated by peristomal metastasis in up to 3% of patients. Overtube-assisted PEG placement might reduce this risk. However, this technique has not been systemically studied for this purpose to date. Methods. Retrospective analysis of consecutive patients with HNC who underwent overtube-assisted PEG placement at Westmead Hospital, Australia, between June 2011 and December 2013. Data were extracted from patients’ endoscopy reports and case notes. We present our technique for PEG insertion and discuss the feasibility and safety of this method. Results. In all 53 patients studied, the PEG tubes were successfully placed using 25 cm long flexible overtubes, in 89% prophylactically (before commencing curative chemoradiotherapy), and in 11% reactively (for treatment of tumor related dysphagia or weight loss). During a median follow-up period of 16 months, 3 (5.7%) patients developed peristomal infection and 3 others developed self-limiting peristomal pain. There were no cases of overtube-related adverse events or overt cutaneous metastases observed. Conclusions. Overtube-assisted PEG placement in patients with HNC is a feasible, simple, and safe technique and might be effective for preventing cutaneous metastasis
Safety and efficacy of overtubes for preventing cutaneous metastasis during PEG tube placement in patients with head and neck cancer : a single-center study
Background: Percutaneous endoscopic gastrostomy (PEG) tubes are commonly placed in head and neck cancer (HNC) patients at risk of malnutrition. However, PEG placement using the ‘pull' technique is complicated by macroscopic and microscopic cutaneous peristomal metastases in 0.5-3% and 9.4%, respectively, leading to a dismal prognosis. Overtube-assisted PEG placement might reduce the risk of cutaneous tumor seeding